A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
A phase 2/3 trial testing LNS8801 in melanoma, now recruiting.
Overview
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma is a phase 2/3 interventional study registered as NCT06624644, led by Linnaeus Therapeutics, and recruiting when checked on 2026-09-11. Official title: A Multicenter, Open-Label, Randomised, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma. Planned enrolment is 135 participants (estimated). The study started in 2025-08-06 and primary completion is expected in 2029-02. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
Shares Melanoma and the tag ctgov-ingest.
- TrialSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma
Shares Melanoma and the tag ctgov-ingest.
- TrialSUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Shares Melanoma and the tag ctgov-ingest.
- TrialIO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Shares Melanoma and the tag ctgov-ingest.
- TrialA Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Shares Melanoma and the tag ctgov-ingest.
- TrialA Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Shares Melanoma and the tag ctgov-ingest.
- TreatmentBA3071
Shares Melanoma and the tag ctgov-ingest.
- TreatmentTRK-950
Shares Melanoma and the tag ctgov-ingest.